Class/mechanism: Anthracycline analog of Daunorubicin (Cerubidine), binds and intercalates between DNA base pairs. Inhibits topoisomerase II activity by stabilizing the DNA-topoisomerase II complex, resulting in single and double strand DNA breaks. May also inhibit polymerase activity and trigger free radical damage to DNA. In comparison to other anthracyclines, idarubicin lacks a methoxy group at position 4 of the anthracycline structure, which results in it having high lipophilicity and an increased rate of cellular uptake compared with other anthracyclines.
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.
Diseases for which it is used
Patient drug information
History of changes in FDA indication
- 9/27/1990: Initial FDA approval
- 12/4/2014 (most recent label available on Drugs @ FDA): "in combination with other approved antileukemic drugs is indicated for the treatment of acute myeloid leukemia (AML) in adults. This includes French-American- British (FAB) classifications M1 through M7."
Also known as
- Generic names: idarubicin comp, idarubicin hydrochloride
- Brand names: Idamycin, Idaru, Ondarubin, Zavedos, Zavedose
- Idarubicin (Idamycin) package insert
- Idarubicin Preservative-Free Solution (Idamycin PFS) package insert
- Idarubicin (Idamycin) package insert (locally hosted backup)
- Idarubicin Preservative-Free Solution (Idamycin PFS) (locally hosted backup)
- Idarubicin (Idamycin) patient drug information (Chemocare)
- Idarubicin (Idamycin) patient drug information (UpToDate)